Abstract

The Cancer Pharmacology Core Facility (CPCF) was established formally in 1995. It exists to enable the translational research objectives of the Cancer Center Developmental Therapeutics Lab Correlates Conference (DTLC). The CPCF does this by providing laboratory capability for drug and metabolite determinations, by providing pharmacokinetic data analysis to guide active trials and advice to trials under development, and by leading in the development of CPCF capabilities necessary to meet the future objectives of the DTLC. The activities and priorities of the Facility are overseen by the DTLC at a scheduled monthly meeting. This regular interaction of the Facility with the clinical investigators and cancer biologists of the DTLC has led directly to improvements in active trials, and to several new pharmacokinetics -based Phase I and Phase II trials scheduled to open during 2000-2001. The Facility obtained NIH BRS instrumentation grant funds to purchase a triple quadrupole mass spectrometer. This instrument capability is central to the Facility's participation in active and planned pharmacokinetics -driven clinical studies. The CPCF plans to expand its pharmacokinetics data analysis capacity and sophistication in proportion to the DTLC's aggressive effort to bring new drugs and treatment concepts to clinical trial.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-13
Application #
6501439
Study Section
Project Start
1991-09-30
Project End
2006-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
13
Fiscal Year
2001
Total Cost
$78,870
Indirect Cost

  Institution

Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106

  Publications

Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726

Showing the most recent 10 out of 1227 publications